MAPKAPK5 and melanoma: This holds significant promise for future clinical translation of these results and confirms a recent report of the effectiveness of GLPG to suppress metastases in xenograft models of breast cancer and melanomas [21], although these authors adopted the previously held explanation that MK5/PRAK exerts its pro-motility effects through the regulation of mTORC1 [55].